FIELD: immunology.
SUBSTANCE: disclosed are chimeric antigenic receptors (CAR) against B cell maturation antigen (BCMA), immunoreactive cells, a nucleic acid molecule, an expression vector, T-cells. What is also presented is a method for reducing a tumor load, methods for increasing or prolonging the survival time of a subject, a method for producing an immunoreactive cell, pharmaceutical compositions, sets for tumor treatment.
EFFECT: present invention can find further application in therapy of various tumors expressing BCMA.
89 cl, 29 dwg, 25 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN AND METHODS OF THE USE THEREOF | 2015 |
|
RU2766094C2 |
| TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
| ANTI-BCMA ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF | 2020 |
|
RU2819660C2 |
| BCMA, NKG2D AND CD16 BINDING PROTEINS | 2018 |
|
RU2805254C2 |
| HUMANIZED ANTIBODY TO BCMA AND BCMA-CAR-T CELLS | 2020 |
|
RU2762942C1 |
| CHIMERIC ANTIGENIC RECEPTORS TO BCMA | 2015 |
|
RU2747457C2 |
| ANTI-BCMA ANTIBODIES CONTAINING ONLY HEAVY CHAIN | 2017 |
|
RU2781301C2 |
| CHIMERIC ANTIGENE RECEPTOR | 2019 |
|
RU2810092C2 |
| BCMA-TARGETED ANTIBODY AND ITS USE | 2018 |
|
RU2799655C2 |
| MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, WHICH SPECIFICALLY BINDS TO BCMA, AND USE THEREOF | 2022 |
|
RU2820350C2 |
